

Rong Fu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5265481/publications.pdf>

Version: 2024-02-01

166
papers

1,012
citations

687363

13
h-index

677142

22
g-index

185
all docs

185
docs citations

185
times ranked

1355
citing authors

#	ARTICLE	IF	CITATIONS
1	Research Progress on NK Cell Receptors and Their Signaling Pathways. <i>Mediators of Inflammation</i> , 2020, 2020, 1-14.	3.0	48
2	CD8 ⁺ T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal9 pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1046-1058.	3.6	43
3	A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 1032-1037.	5.6	38
4	Multiple Myeloma-Derived Exosomes Inhibit Osteoblastic Differentiation and Improve IL-6 Secretion of BMSCs from Multiple Myeloma. <i>Journal of Investigative Medicine</i> , 2020, 68, 45-51.	1.6	37
5	Current research status of HLA in immune-related diseases. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 340-350.	2.7	35
6	Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. <i>Frontiers in Oncology</i> , 2020, 10, 1595.	2.8	33
7	Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. <i>Cancer Cell International</i> , 2014, 14, 132.	4.1	31
8	Abnormal quantity and function of regulatory T cells in peripheral blood of patients with severe aplastic anemia. <i>Cellular Immunology</i> , 2015, 296, 95-105.	3.0	30
9	CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodelling in vivo in myeloma bone disease. <i>International Journal of Oncology</i> , 2017, 50, 631-639.	3.3	26
10	Elevated TIM3 ⁺ hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis. <i>Leukemia Research</i> , 2014, 38, 714-721.	0.8	21
11	Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8 ⁺ T lymphocyte function through the STAT3-ARG1 pathway. <i>Leukemia and Lymphoma</i> , 2021, 62, 218-223.	1.3	19
12	Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway. <i>Oncology Letters</i> , 2018, 15, 4079-4086.	1.8	17
13	Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2017, 106, 248-257.	1.6	16
14	NK cells suppress CD8 ⁺ T cell immunity via NKG2D in severe aplastic anemia. <i>Cellular Immunology</i> , 2019, 335, 6-14.	3.0	16
15	Abnormal histone acetylation of CD8 ⁺ T cells in patients with severe aplastic anemia. <i>International Journal of Hematology</i> , 2016, 104, 540-547.	1.6	14
16	PKM2 Is Required to Activate Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-9.	4.0	14
17	Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23008.	2.1	14
18	Bone marrow-derived mesenchymal stem cells inhibit CD8 ⁺ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. <i>Clinical and Experimental Immunology</i> , 2021, 205, 53-62.	2.6	14

#	ARTICLE	IF	CITATIONS
19	Role and Function of T Cell-Derived Exosomes and Their Therapeutic Value. <i>Mediators of Inflammation</i> , 2021, 2021, 1-7.	3.0	14
20	Erythroblastic Islands in the Bone Marrow of Patients with Immune-Related Pancytopenia. <i>PLoS ONE</i> , 2014, 9, e95143.	2.5	12
21	Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes. <i>Oncology Letters</i> , 2016, 11, 2347-2352.	1.8	12
22	Paraneoplastic Evans syndrome in a patient with adenocarcinoma of the lung: A case report. <i>Thoracic Cancer</i> , 2017, 8, 57-60.	1.9	12
23	TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8 ⁺ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome. <i>Immunology</i> , 2023, 168, 273-289.	4.4	12
24	Decreased TIM-3 expression of peripheral blood natural killer cells in patients with severe aplastic anemia. <i>Cellular Immunology</i> , 2017, 318, 17-22.	3.0	11
25	Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 67, 12-16.	0.8	11
26	Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes. <i>Oncology Letters</i> , 2018, 15, 5497-5504.	1.8	11
27	The clinical characteristics and therapy response of patients with acquired pure red cell aplasia. <i>Hematology</i> , 2018, 23, 639-645.	1.5	11
28	Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22888.	2.1	11
29	CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3 β /cyclinD1 signal pathway in Myeloma Bone Disease. <i>Cancer Medicine</i> , 2020, 9, 737-744.	2.8	11
30	IgG autoantibody subclasses altered in immuno-related hemocytopenia. <i>Cellular Immunology</i> , 2015, 294, 13-20.	3.0	10
31	The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 216-226.	0.6	10
32	Everolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway. <i>Journal of Investigative Medicine</i> , 2019, 67, 39-47.	1.6	10
33	Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis. <i>Journal of Investigative Medicine</i> , 2019, 67, 1067-1075.	1.6	9
34	Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF- κ B Signal Pathways. <i>Frontiers in Oncology</i> , 2020, 10, 584530.	2.8	9
35	Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes. <i>Innate Immunity</i> , 2020, 26, 703-715.	2.4	9
36	Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/ β -Catenin Pathway. <i>Stem Cells International</i> , 2020, 2020, 1-16.	2.5	9

#	ARTICLE	IF	CITATIONS
37	CTLA4 and HLA-DQ are key molecules in the regulation of mDC-mediated cellular immunity by Tregs in severe aplastic anemia. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23443.	2.1	9
38	Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma. <i>International Journal of Molecular Medicine</i> , 2020, 45, 1112-1120.	4.0	9
39	Involvement of MM cell-derived exosomes in T lymphocytes immune responses. <i>Oncology Letters</i> , 2020, 20, 31.	1.8	9
40	A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults. <i>International Journal of Hematology</i> , 2016, 104, 462-467.	1.6	8
41	The shortening telomere length of T lymphocytes maybe associated with hyperfunction in severe aplastic anemia. <i>Molecular Medicine Reports</i> , 2018, 17, 1015-1021.	2.4	8
42	Screening novel autoantigens targeted by serum IgG autoantibodies in immunorelated pancytopenia by SEREX. <i>International Journal of Hematology</i> , 2017, 106, 622-630.	1.6	8
43	Lower level of IL-35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs test-positive hemocytopenia. <i>Molecular Medicine Reports</i> , 2017, 17, 2973-2981.	2.4	8
44	Abnormal expression and mutation of the RBPJ gene may be involved in CD59 clonal proliferation in paroxysmal nocturnal hemoglobinuria. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 4536-4546.	1.8	8
45	Bone Marrow Plasma Cytokine Signature Profiles in Severe Aplastic Anemia. <i>BioMed Research International</i> , 2020, 2020, 1-11.	1.9	8
46	Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China. <i>Leukemia and Lymphoma</i> , 2021, 62, 2657-2664.	1.3	8
47	Preliminary Study of the Relationship Between EPO Receptor and Autoantibody on the Membrane of Erythropoietic Cells of the Patients with BMMNC- Coomb's Test(+) Hemocytopenia. <i>Blood</i> , 2010, 116, 4436-4436.	1.4	8
48	TRAIL in CD8+ T cells from patients with severe aplastic anemia. <i>International Journal of Hematology</i> , 2017, 106, 490-499.	1.6	7
49	Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23922.	2.1	7
50	Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. <i>Age and Ageing</i> , 2022, 51, .	1.6	7
51	Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/CTLA-1 pathway in multiple myeloma. <i>Cancer Medicine</i> , 2022, 11, 4838-4848.	2.8	7
52	Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease. <i>Annals of Hematology</i> , 2016, 95, 1099-1106.	1.8	6
53	Deep sequencing of whole genome exon in paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2017, 92, E51-E53.	4.1	6
54	Transforming growth factor 15 increased in severe aplastic anemia patients. <i>Hematology</i> , 2017, 22, 548-553.	1.5	6

#	ARTICLE	IF	CITATIONS
55	De-escalation empirical antibiotic therapy improved survival for patients with severe aplastic anemia treated with antithymocyte globulin. <i>Medicine (United States)</i> , 2017, 96, e5905.	1.0	6
56	Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Clinical Drug Investigation</i> , 2017, 37, 167-174.	2.2	6
57	The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF- κ B pathway in multiple myeloma cells. <i>International Journal of Molecular Medicine</i> , 2019, 43, 285-293.	4.0	6
58	Gene mutations associated with thrombosis detected by whole-exome sequencing in paroxysmal nocturnal hemoglobinuria. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 424-432.	1.3	6
59	Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome. <i>Journal of Investigative Medicine</i> , 2019, 67, 1125-1130.	1.6	6
60	Effects of Shikonin on the Functions of Myeloid Dendritic Cells in a Mouse Model of Severe Aplastic Anemia. <i>Mediators of Inflammation</i> , 2020, 2020, 1-10.	3.0	6
61	The dysfunction of platelets in paroxysmal nocturnal hemoglobinuria. <i>Thrombosis Research</i> , 2016, 148, 50-55.	1.7	5
62	Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. <i>International Journal of Clinical Oncology</i> , 2017, 22, 585-592.	2.2	5
63	High serum levels of complements C3 and C4 as novel markers for myeloma bone disease. <i>Annals of Hematology</i> , 2017, 96, 331-333.	1.8	5
64	The Risk of Clonal Evolution of Granulocyte Colony-Stimulating Factor for Acquired Aplastic Anemia: A Systematic Review and Meta-Analysis. <i>Acta Haematologica</i> , 2018, 140, 141-145.	1.4	5
65	Epstein Barr Virus Infection Affects Function of Cytotoxic T Lymphocytes in Patients with Severe Aplastic Anemia. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	5
66	Proteomics analysis reveals alterations of NK cells in patients with severe aplastic anemia. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 308-315.	1.3	5
67	Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 949-954.	2.9	5
68	Expression and function of SLAMF6 in CD8+ T lymphocytes of patients with severe aplastic anemia. <i>Cellular Immunology</i> , 2021, 364, 104343.	3.0	5
69	Upregulated Expression of Profilin1 on Dendritic Cells in Patients With Severe Aplastic Anemia. <i>Frontiers in Immunology</i> , 2021, 12, 631954.	4.8	5
70	Plasma Metabolomic and Intestinal Microbial Analyses of Patients With Severe Aplastic Anemia. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 669887.	3.7	5
71	Complement C3a activates osteoclasts by regulating the PI3K/PDK1/S6K3 pathway in patients with multiple myeloma. <i>Cancer Biology and Medicine</i> , 2021, 18, 721-733.	3.0	5
72	Antibodies specific to ferritin light chain polypeptide are frequently detected in patients with immune-related pancytopenia. <i>Molecular Medicine Reports</i> , 2020, 22, 2012-2020.	2.4	5

#	ARTICLE	IF	CITATIONS
73	Role of B lymphocyte and its subpopulations in pathogenesis of immunorelated pancytopenia. Chinese Medical Sciences Journal, 2007, 22, 199-202.	0.4	5
74	Hodgkin's lymphoma associated with myelofibrosis: A case report. Oncology Letters, 2015, 10, 1551-1554.	1.8	4
75	High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1 α signaling pathway. Oncology Letters, 2019, 17, 5395-5402.	1.8	4
76	Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis. Journal of Clinical Laboratory Analysis, 2020, 34, e23057.	2.1	4
77	Infection risk in autoimmune hematological disorders with low-dose rituximab treatment. Journal of Clinical Laboratory Analysis, 2020, 34, e23455.	2.1	4
78	<p>Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China</p>. Cancer Management and Research, 2020, Volume 12, 8935-8941.	1.9	4
79	Th9 Cells in Peripheral Blood Increased in Patients with Immune-Related Pancytopenia. Journal of Immunology Research, 2020, 2020, 1-8.	2.2	4
80	Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2021, 35, e23667.	2.1	4
81	Upregulated expression of leukocyte immunoglobulin-like receptor 3 in patients with severe aplastic anemia. Experimental and Therapeutic Medicine, 2021, 21, 346.	1.8	4
82	Role of EZH2 in Bone Marrow Mesenchymal Stem Cells and Immune-Cancer Interactions. Critical Reviews in Oncology/Hematology, 2021, 169, 103547.	4.4	4
83	Abnormal expression of histone acetylases in CD8+ T cells of patients with severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2022, 36, e24339.	2.1	4
84	CD56 ^{bright} natural killer cells exhibit abnormal phenotype and function in severe aplastic anemia. International Journal of Laboratory Hematology, 2019, 41, 353-363.	1.3	3
85	Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma. Cytometry Part B - Clinical Cytometry, 2022, 102, 44-49.	1.5	3
86	lncRNA MSTRC.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	4.0	3
87	Availability of NK cell expansion agent combined with recombinant IL-2 and IL-15 stimulation on the expansion and high-purity of NK cells in patients with immune-related pancytopenia <i>in vitro</i> . Molecular Medicine Reports, 2019, 20, 4358-4366.	2.4	3
88	A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis. Experimental Hematology and Oncology, 2022, 11, 1.	5.0	3
89	Expression and function of hematopoiesis-stimulating factor receptors on the GPI ⁺ and GPI ⁺ hematopoietic stem cells of patients with paroxysmal nocturnal hemoglobinuria/aplastic anemia syndrome. Experimental and Therapeutic Medicine, 2016, 11, 1668-1672.	1.8	2
90	Abnormal changes in the quantity and function of osteoblasts cultured <i>in vitro</i> in patients with myelodysplastic syndrome. Oncology Letters, 2018, 16, 4384-4390.	1.8	2

#	ARTICLE	IF	CITATIONS
91	Effects of Epstein-Barr Virus Infection on CD19+ B Lymphocytes in Patients with Immunorelated Pancytopenia. <i>Journal of Immunology Research</i> , 2020, 2020, 1-9.	2.2	2
92	The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia. <i>Blood</i> , 2019, 134, 3747-3747.	1.4	2
93	CD8+HLA-DR+ T Cells Are Increased in Patients with Severe Aplastic Anemia. <i>Blood</i> , 2012, 120, 4395-4395.	1.4	2
94	Abnormal numbers of CD4+ T lymphocytes and abnormal expression of CD4+ T lymphocyteâ€secreted cytokines in patients with immuneâ€related haemocytopenia. <i>Molecular Medicine Reports</i> , 2019, 20, 3979-3990.	2.4	2
95	Single wholeâ€genome sequencing analysis of metastatic biopsy is sufficient for investigational treatment opportunities in cancer. <i>Cancer Communications</i> , 2021, , .	9.2	2
96	Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China. <i>Hematology</i> , 2021, 26, 874-880.	1.5	2
97	SUZ12 participates in the proliferation of PNH clones by regulating histone H3K27me3 levels. <i>Journal of Leukocyte Biology</i> , 2022, 112, 243-255.	3.3	2
98	Clinical observation of lowâ€dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A singleâ€center retrospective analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24239.	2.1	2
99	Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease. <i>Journal of Investigative Medicine</i> , 2022, , jim-2021-002192.	1.6	2
100	Identification of potential pathogenic genes for severe aplastic anemia by wholeâ€exome sequencing. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24438.	2.1	2
101	Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-21.	4.0	2
102	Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 2525-2532.	1.8	1
103	Expression of C1q in the serum of patients with nonâ€severe aplastic anemia, and its association with disease severity. <i>Molecular Medicine Reports</i> , 2019, 19, 1194-1202.	2.4	1
104	The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure. <i>Journal of Immunology Research</i> , 2020, 2020, 1-10.	2.2	1
105	Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes. <i>Frontiers in Oncology</i> , 2020, 10, 962.	2.8	1
106	The Role of lncRNA AF117829.1 in the Immunological Pathogenesis of Severe Aplastic Anaemia. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-19.	4.0	1
107	Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from MDS Patients and Promotes Leukemia Transformation. <i>Blood</i> , 2019, 134, 5398-5398.	1.4	1
108	The Expression and Clinical Significance of PRAME Gene in Acute Leukemia.. <i>Blood</i> , 2007, 110, 4225-4225.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Study on the Dendritic Cell Subsets and Their Relationship with the Expressions of T-Bet and GATA-3 in Peripheral Lymphocytes of Severe Aplastic Anemia Patients. <i>Blood</i> , 2008, 112, 4901-4901.	1.4	1
110	Study of the Quantity and Function of Regulatory T Cells In the Hemocytopenic Patients with Positive BMMNC-Coombs Test. <i>Blood</i> , 2010, 116, 4875-4875.	1.4	1
111	TET2 Gene Expression in Bone Marrow Cells in Myelodysplastic Syndromes Patients and the Effect of Silencing TET2 by siRNA On Biological Characteristics of Healthy CD34+ Cells. <i>Blood</i> , 2012, 120, 4934-4934.	1.4	1
112	Increased Population Of Myeloid-Derived Suppressor Cells In Patients With Myelodysplastic Syndromes Overexpress ARG1 and Mediate CD8+ T Cell Inhibition. <i>Blood</i> , 2013, 122, 5212-5212.	1.4	1
113	Zoledronic Acid Inhibits Cell Growth of Multiple Myeloma Cells and Shows Synergistic Antimyeloma Effects with Bortezomib Via CD38 /cADPR /Ca2+ /Ras /Pakt /NF-Kb /Pim-2 Pathway. <i>Blood</i> , 2015, 126, 5311-5311.	1.4	1
114	The Role of PKM2 in the Activation of Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. <i>Blood</i> , 2016, 128, 1497-1497.	1.4	1
115	Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study. <i>Blood</i> , 2019, 134, 5493-5493.	1.4	1
116	Pyruvate Kinase M2 Regulates Hif-1alpha Activity in Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. <i>Blood</i> , 2021, 138, 1109-1109.	1.4	1
117	BMSCs Regulate the Function of NK Cell By CD155/Tigit/CD226 Pathway in MDS Patients. <i>Blood</i> , 2021, 138, 4651-4651.	1.4	1
118	New Trends of Nontransplant therapy for Acquired Aplastic Anemia. <i>Current Pharmaceutical Design</i> , 2022, 28, .	1.9	1
119	Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. <i>Investigational New Drugs</i> , 2022, 40, 738-746.	2.6	1
120	Pseudo-monoclonal gammopathy due to autoimmune disease: a case report. <i>Journal of International Medical Research</i> , 2020, 48, 030006051986661.	1.0	0
121	Long Non-coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients. <i>Turkish Journal of Haematology</i> , 2021, 38, 236-238.	0.5	0
122	The Auto-Antibodies on Bone Marrow Cells in the Patients with Systemic Lupus Erythematosus.. <i>Blood</i> , 2006, 108, 3856-3856.	1.4	0
123	Proliferative Function of Bone Marrow Hematopoietic Stem Cells of Patients with Systemic Lupus Erythematosus.. <i>Blood</i> , 2006, 108, 3857-3857.	1.4	0
124	An Analysis of Occurrence and Prognosis Related Factors of Renal Dysfunction in Patients with Multiple Myeloma.. <i>Blood</i> , 2007, 110, 4732-4732.	1.4	0
125	Study on the Ratio and Function of Macrophages in the Patients with BMMNCCoombs Test(+) Hematocytopenia. <i>Blood</i> , 2008, 112, 4656-4656.	1.4	0
126	In Vitro Study of the Function of Dendritic Cells on Stimulating T Lymphocytes Proliferation in Severe Aplastic Anemia. <i>Blood</i> , 2008, 112, 4919-4919.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Study on the Mechanism of ϵ - HbA_{1c} Formation in the Bone Marrow Smears of the Patients with BMMNC-Coombs Test(+) Hematocytopenia. Blood, 2008, 112, 4753-4753.	1.4	0
128	Expression of CD123 and CD114 on the Bone Marrow Cells of Patients with Myelodysplastic Syndromes. Blood, 2010, 116, 4966-4966.	1.4	0
129	Expression of <i>dlk1</i> in the Bone Marrow Cells of Patients with Myelodysplastic Syndrome and Its Clinical Significance. Blood, 2011, 118, 5042-5042.	1.4	0
130	Preliminary Study of the Autoantigens on the Membrane of Erythropoietic Cells of the Patients with BMMNC- Coombs Test(+) Hemocytopenia. Blood, 2011, 118, 4382-4382.	1.4	0
131	The Somatic Mutation of <i>PIG-A</i> Gene and the Expressions of <i>EGR-1</i> and <i>WT1</i> Genes in Bone Marrow Cells of the Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2011, 118, 4379-4379.	1.4	0
132	Chemotherapy Plus Hematopoietic Growth Factor for Refractory Paroxysmal Nocturnal Hemoglobinuria: Diminishing PNH Clone and Stimulating Hematopoiesis. Blood, 2011, 118, 4376-4376.	1.4	0
133	Study on the Pathways to Damage Hematopoiesis by CD8+ Effector T Cells of the Patients with Severe Aplastic Anemia. Blood, 2011, 118, 4371-4371.	1.4	0
134	TET2 mRNA Expression in Bone Marrow Mononuclear Cells of the Patients with Myelodysplastic Syndromes and it's Clinical Significances. Blood, 2011, 118, 5036-5036.	1.4	0
135	Study on the Quantities and Functions of Natural Killer Cell Subsets in Peripheral Blood of the Patients with Severe Aplastic Anemia., Blood, 2011, 118, 3423-3423.	1.4	0
136	The Expressions of CD114, CD117 and STAT5 in CD34+CD59 ⁺ and CD34+CD59 ⁻ Bone Marrow Cells of the Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2012, 120, 4404-4404.	1.4	0
137	Expression and Clinical Significance of Notch1 On the Membrane of Bone Marrow CD38+CD138+Plasma Cells in the Patients with Multiple Myeloma. Blood, 2012, 120, 4981-4981.	1.4	0
138	The Study Of The Effect and Mechanism Of Chemotherapy Plus Granulocyte Colony Stimulating Factor (DAG) for Refractory Paroxysmal Nocturnal Hemoglobinuria In Vitro. Blood, 2013, 122, 4717-4717.	1.4	0
139	Abnormal Expression Of Shelterin Is Associated With Short Telomere and Immune Disorder In Severe Aplastic Anemia. Blood, 2013, 122, 5562-5562.	1.4	0
140	The Mechanisms Of Damage To Bone Marrow By Iron Overload In Patients With Immuno-Related Pancytopenia. Blood, 2013, 122, 5561-5561.	1.4	0
141	Vitro Culture and Regulation Of Osteoblasts and Cellular Immunity Function In Multiple Myeloma patients. Blood, 2013, 122, 5329-5329.	1.4	0
142	Recombinant Human Thrombopoietin Promotes The Recovery Of Megakaryocyte Lineage In Patients With Severe Aplastic Anemia Receiving Immunosuppressive Therapy. Blood, 2013, 122, 2437-2437.	1.4	0
143	Decreased Tim-3 Expression Level of Peripheral Blood Natural Killer Cells in Severe Aplastic Anemia. Blood, 2015, 126, 4767-4767.	1.4	0
144	Expression of Activated Molecules on CD5+ b Cells in Autoimmune Hemolytic Anemia. Blood, 2015, 126, 4765-4765.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Decreased TIM-3 Expression Level of Peripheral Blood Natural Killer Cells in Severe Aplastic Anemia. Blood, 2016, 128, 5078-5078.	1.4	0
146	MM-derived exosomes can promote apoptosis and inhibit proliferation of HD-CD4+T, inhibit apoptosis and promote proliferation but inhibit perforin secretion of HD-CD8+T, inhibit apoptosis and promote proliferation HD-Treg, and promotes IL-10 secretion. Blood, 2018, 132, 5602-5602.	1.4	0
147	Study of TIM-3 in Pathogenesis of Myelodysplastic Syndrome. Blood, 2018, 132, 4388-4388.	1.4	0
148	The Effect of Pyruvate Kinase M2: Inhibitor(shikonin) on the Function of Mdc in Severe Aplastic Anemia Mouse Model. Blood, 2019, 134, 5021-5021.	1.4	0
149	Adiponectin Inhibits the Differentiation and Maturation of Osteoclasts Via mTOR Pathway in Multiple Myeloma. Blood, 2019, 134, 5521-5521.	1.4	0
150	Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma. Blood, 2019, 134, 4416-4416.	1.4	0
151	The Study of Proliferation Relative Long Non-Coding RNA in CD59- Cell from Paroxysmal Nocturnal Hemoglobinuria Patients. Blood, 2019, 134, 5023-5023.	1.4	0
152	Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients. Blood, 2021, 138, 4783-4783.	1.4	0
153	Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China. Blood, 2021, 138, 4728-4728.	1.4	0
154	Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China. Blood, 2021, 138, 4766-4766.	1.4	0
155	The Role of TLR4 Inducing Macrophage Pyroptosis in the Pathogenesis of Severe Aplastic Anemia. Blood, 2021, 138, 1114-1114.	1.4	0
156	SUZ12 Participates in PNH Cloning Proliferation By Regulating Histone H3K27me3 Methylation Level. Blood, 2021, 138, 1106-1106.	1.4	0
157	Study of Bone Marrow Mesenchymal Stem Cells Regulating NK Cells Function through Tigit/ CD226 in Patients with Multiple Myeloma. Blood, 2021, 138, 2685-2685.	1.4	0
158	Bone Marrow-Derived Mesenchymal Stem Cells Inhibit CD8+ t Cell Immune Responses Via PD-1/PD-L1 Pathway in Multiple Myeloma. Blood, 2020, 136, 53-54.	1.4	0
159	Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals. Blood, 2020, 136, 5-6.	1.4	0
160	Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study. Blood, 2020, 136, 38-39.	1.4	0
161	The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure. Blood, 2020, 136, 10-11.	1.4	0
162	The Study of Proliferation Relative Long Non-Coding RNA FAM157C in CD59- cell from Paroxysmal Nocturnal Hemoglobinuria Patients. Blood, 2020, 136, 33-34.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis. Journal of Investigative Medicine, 2021, , jim-2021-002147.	1.6	0
164	Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia. Disease Markers, 2022, 2022, 1-10.	1.3	0
165	Ferritin Light Chain: A Candidate Autoantigen in Immuno-Related Pancytopenia. Frontiers in Immunology, 2022, 13, 851096.	4.8	0
166	Gene therapy with B-cell maturation antigen/ <sc>CD3</sc> bispecific antibody encoding plasmid <sc>DNA</sc> for treating multiple myeloma. British Journal of Haematology, 0, , .	2.5	0